NCT03309007View on ClinicalTrials.gov

A Double-Blind, Placebo-Controlled Trial of Anti-Aging, Pro-Autophagy Effects of Metformin in Adults With Prediabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 1, 2017

Primary Completion Date

August 20, 2020

Study Completion Date

August 20, 2020

Conditions
PreDiabetesAging
Interventions
DRUG

Metformin

Total daily dose titrated up to 1500 mg po q day over the course of 4 weeks and continued for a total exposure of 12 weeks.

DRUG

Placebo Oral Tablet

Total daily dose titrated up to 1944 mg po q day over the course of 4 weeks and continued for a total exposure of 12 weeks.

Trial Locations (1)

87131

University of New Mexico Clincal & Translational Science Center, Albuquerque

All Listed Sponsors
lead

University of New Mexico

OTHER

NCT03309007 - A Double-Blind, Placebo-Controlled Trial of Anti-Aging, Pro-Autophagy Effects of Metformin in Adults With Prediabetes | Biotech Hunter | Biotech Hunter